P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Thierry Facon,Shaji Kumar,Torben Plesner,Robert Z. Orlowski,Philippe Moreau,Nizar J. Bahlis,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Aurore Perrot,Katja Weisel,Noopur Raje,Margaret Macro,Laurent Frenzel,Xavier Leleu,Jianping Wang,Rian Van Rampelbergh,Clarissa M. Uhlar,Jessica Vermeulen,Joana Duran,Fredrik Borgsten,Saad Z. Usmani +23 more
TL;DR: The MAIA study as discussed by the authors showed that patients with newly diagnosed multiple myeloma who took daratumumab plus lenalidomide and dexamethasone lived longer and decreased their protein levels.
P935: real world comparative analysis of the efficacy of teclistamab versus current treatments in patients with triple-class exposed relapsed/refractory multiple myeloma from the locomotion study
Hermann Einsele,Philippe Moreau,Margaux Delforge,N. W. van de Donk,Francesca Ghilotti,Joris Diels,Ahmed Elsada,Vadim Strulev,Lixia Pei,Rachel Kobos,Jennifer Smit,Mary Slavcev,Katja Weisel,M.V. Mateos +13 more
TL;DR: Teclistamab (tec), a B-cell maturation antigen × CD3 bispecific antibody, is currently being evaluated in the MajesTEC-1 study, a single-arm, phase 1/2 study in patients with TCE RRMM.
Journal ArticleDOI
2-[18F]FDG PET/CT Flare-up Phenomena Following T-Cell Engager Bispecific Antibody in Multiple Myeloma.
TL;DR: In this paper , 2-[18F] FDG PET/CT imaging was performed on a 61-year-old woman with relapsed myeloma to determine metabolic response to talquetamab, a GPRC5DxCD3bispecific antibody.
Journal ArticleDOI
Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
David Sharon,Fengjiao Dunbar,Paul Jung,Xifeng Wang,Xiaotong Li,Christine Mantis,Orlando F. Bueno,Cyrille Touzeau,Philippe Moreau,Simon J. Harrison,Luciano J. Costa,Jonathan L. Kaufman,Nizar J. Bahlis,Shaji Kumar,Jeremy A. Ross,Pearlie K. Epling-Burnette +15 more
TL;DR: In this paper , the authors investigated the relationship between B-cell differentiation and Ven sensitivity in relapsed/refractory multiple myeloma (RRMM) patients, using an integrated approach of transcriptomic and metabolomic profiling.
Journal ArticleDOI
P960: health-related quality of life in the locommotion study of real-life current standard of care in patients with relapsed/refractory multiple myeloma
Margaux Delforge,Philippe Moreau,Hermann Einsele,Virgilio De Stefano,J. Lindsey-Hill,Laure Vincent,Silvia Mangiacavalli,A. Perrot,Enrique M. Ocio,S. ten Seldam,E. I. ’. Groen-Damen,M. Semerjian,Vadim Strulev,J. Schecter,Tito Roccia,Katharine S. Gries,Tonia Nesheiwat,Robert Wapenaar,M.V. Mateos,Katja Weisel +19 more
TL;DR: This first prospective study of real-life current SOC in triple-class exposed patients with RRMM reported limited gains in HRQoL, most notably in pain symptoms, and there is an urgent and unmet need for therapies that lead to deep responses and delayed disease progression, as these are associated with improvements in HRqoL